Citations

Institution: Mayo Clinic Clear

Showing 10 of 108104 citations.

Advancements in Visual Field Testing: A Systematic Review of the 24-2C Test Grid
Jin, Eric , Wong, Natalie Shi Qi , Goh, Claire Xin Yi, Stewart, Michael W., Dorairaj, Syril, Ang, Bryan Chin Hou , Ang, Bryan C H , Dorairaj, Syril

Bioengineering | July 1, 2025 | Volume: 12 | Issue: 7 | Pages: 711

10.3390/bioengineering12070711 | PMID 40722403 Get It

A systematic review was conducted of studies published up to 30 August 2024. Studies comparing conventional visual field (VF) indices, ability to detect central visual field defects (CVFDs), structure–function (S-F) concordance, and test characteristics across the HVF 24-2C SITA-Faster, 24-2 SITA-Standard/Faster, and 10-2 SITA-Standard/Fast tests were included. Eight studies with 1239 subjects (49.1% male; mean age, 54.8–66.9 years) were analyzed. The 24-2C produced similar global VF indices compared to the 10-2 and 24-2 (Standard/Faster) (ICC = 0.95 and 0.80, p < 0.001), detected more VF defects and CVFD clusters, and demonstrated greater S-F concordance than the 24-2 (Standard/Faster). Although the 10-2 (Standard/Fast) detected significantly more CVFDs and had a greater S-F concordance, the agreement between the 24-2C and 10-2 grids was substantial (ĸ = 0.488 to 0.708). The 24-2C was also faster compared to the 24-2 Standard and 10-2 (Standard/Fast), with comparable false positives, higher false negatives, and fewer fixation losses than the 24-2 Standard. In conclusion, the HVF 24-2C is quicker and identifies more CVFDs than the 24-2 grid, demonstrates high agreement with the 10-2 grid, and aids in CVFD screening.
The PIEE Cycle: A Structured Framework for Red Teaming Large Language Models in Clinical Decision-Making
Trabilsy, Maissa , Prabha, Srinivasagam , Haider, Syed Ali , Genovese, Ariana , Wood, Nadia , Gopala, Narayanan, Tao, Cui , Forte, Antonio J. , Haider, Syed A , Genovese, Ariana , Wood, Nadia , Tao, Cui , Forte, Antonio Jorge , Prabha, Srinivagasam , Gomez-Cabello, Cesar A. , Borna, Sahar

Bioengineering | July 1, 2025 | Volume: 12 | Issue: 7 | Pages: 706

10.3390/bioengineering12070706 | PMID 40722398 Get It

The increasing integration of large language models (LLMs) into healthcare presents significant opportunities, but also critical risks related to patient safety, accuracy, and ethical alignment. Despite these concerns, no standardized framework exists for systematically evaluating and stress testing LLM behavior in clinical decision-making. The PIEE cycle—Planning and Preparation, Information Gathering and Prompt Generation, Execution, and Evaluation—is a structured red-teaming framework developed specifically to address artificial intelligence (AI) safety risks in healthcare decision-making. PIEE enables clinicians and informatics teams to simulate adversarial prompts, including jailbreaking, social engineering, and distractor attacks, to stress-test language models in real-world clinical scenarios. Model performance is evaluated using specific metrics such as true positive and false positive rates for detecting harmful content, hallucination rates measured through adapted TruthfulQA scoring, safety and reliability assessments, bias detection via adapted BBQ benchmarks, and ethical evaluation using structured Likert-based scoring rubrics. The framework is illustrated using examples from plastic surgery, but is adaptable across specialties, and is intended for use by all medical providers, regardless of their backgrounds or familiarity with artificial intelligence. While the framework is currently conceptual and validation is ongoing, PIEE provides a practical foundation for assessing the clinical reliability and ethical robustness of LLMs in medicine.
Antiretroviral Therapy and Risk of Stroke in People with HIV in Zambia
Zimba, Stanley , Ngalamika, Owen , Mukambo, Emmanuel , Shankanga, Theresa , Msimuko, Taonga, Mwansa, Diwell , Mulenga, Bwalya , Chisha, Mike, Chomba, Mashina , Chishimba, Lorraine , Atadzhanov, Masharip , Saylor, Deanna , Saylor, Deana , Msimuko, Taonga, Asukile, Melody Tunsubilege , Kayamba, Violet J. , Mulenga, Lloyd , Siddiqi, Omar K. , Ross, Owen A.

No container title available | July 1, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6945551/v1 | PMID 40630544 Get It

Abstract Background People with HIV (PWH) are at increased risk of stroke likely due to many factors including antiretroviral therapy (ART). We sought to evaluate the association between ARTand risk of stroke in PWH. Methods We conducted a prospective case-control study at the University Teaching Hospital in Lusaka, Zambia between March 2022 and October 2024 in PWH comparing those with stroke (cases) and without (controls) matched (1:2) for age, sex and race. Standardized data collection instruments were used to collect demographic, clinical, laboratory and imaging information. Comparisons were made between the cases and controls, and subgroup analysis by ART duration was done for the cases. Results We analyzed results for 205 cases and 410 controls. Compared to controls, cases were more likely to have hypertension (71% vs. 18%, p=0.001), lower CD4 counts [293(163-592) cells/µl vs. 533 (376-688) cells/µl, p=0.0001] and to be on second line ART (23% vs. 4%, p=0.001). Hypertension (aOR 19.7, 95% CI 3.1-126.4, p=0.002) and Tenofovir Disoproxil Fumarate (TDF) use (aOR 85.3, 95% CI 5.3-1380.7, p=0.002) were associated with increased odds of stroke, whereas Dolutegravir (aOR 0.03, 95% CI 0.001-0.58, p=0.02) and alcohol use (aOR 0.24, 95% CI 0.06-0.95) were associated with reduced odds of stroke. The majority of stroke patients on long-term ART were using Dolutegravir (80% vs. 35%, p=0.001) and TDF (72% vs. 42%, p=0.01). Conclusion In PWH, TDF associates with higher odds of stroke. Although Dolutegravir associates with reduced odds of stroke, stroke patients on long-term ART are more likely to be on it.
Endoscopic vs. External Dacryocystorhinostomy in Granulomatosis with Polyangiitis: A Scoping Review of the Literature and Our Experience with Endoscopic Dacryocystorhinostomy
Kumar, Nitish , Marks, Lisa , Gomes, Pedro Lança , Marks, Lisa A , Lança Gomes, Pedro , Kumar, Nitish , Lal, Devyani

Journal of Personalized Medicine | July 1, 2025 | Volume: 15 | Issue: 7 | Pages: 278

10.3390/jpm15070278 | PMID 40710395 Get It

Background/Objectives: Although endoscopic dacryocystorhinostomy (DCR) has been widely accepted as the procedure of choice for nasolacrimal duct obstruction (NLDO) management due to most etiologies, concerns regarding the reactivation of disease and involvement of surrounding structures add to hesitation in its utilization for granulomatosis with polyangiitis (GPA) patients. No study has directly compared outcomes of external vs. endoscopic DCR in GPA patients. This information can be helpful for patient counselling and choosing a personalized surgical approach for the best results. Methods: A scoping review of the literature was performed in January 2024. The following databases were searched using a combination of MeSH (Medical Subject Headings) and keywords: Ovid MEDLINE, Ovid EMBASE, Scopus, and Web of Science. This scoping review is not registered. Medical records of two GPA patients who underwent endoscopic DCR at our center were reviewed. Results: The search yielded 96 articles; 15 articles met the inclusion criteria for a full review. Six studies with 22 procedures reported 100% success with endoscopic DCR. Nine studies with 122 procedures reported success in 88.5% of cases with external DCRs. Additional perioperative immunosuppression was recommended in patients with severe mucosal inflammation. The case series presents the disease course, details of surgery, and perioperative management in two GPA patients with NLDO who underwent endoscopic DCR successfully. Conclusions: Endoscopic DCR was associated with equivalent or better success rates and lower complications compared to external DCR in GPA patients. Ensuring disease remission state and appropriate immunomodulatory therapy can help prevent the proposed risk of endonasal disease reactivation with endoscopic DCR.
Cerium Oxide Nanozymes: Exploring Synthesis, Catalytic Activity, and Biomedical Potential
Cai, Yuyao, Ren, Wenqi , Du, Chunshui , Zhang, Jinghan , Zhao, Yuxiao, Kang, Haoyu, Ge, Xiaotong, Li, Si , Jiang, Tingting , Jiang, Tingting , Du, Chenxi, Zhao, Yuxiao, Yu, Jiaqi , Du, Haoze, Lu, Min

Small | July 1, 2025 | Volume: 21 | Issue: 34 | Pages: No page available

10.1002/smll.202504436 | PMID 40590173 Get It

Abstract Cerium oxide (CeO 2 ) nanozymes have emerged as a novel class of nanozyme materials distinguished by their tunable valence states (Ce 3+ /Ce 4+ ) and abundant surface oxygen vacancies (OVs), demonstrating exceptional chemical stability, cost‐effectiveness, and scalable manufacturability. Precise control of reaction temperature or implementation of carrier‐mediated crystal growth strategies effectively enhances nanoparticle dispersion and mitigates aggregation. This review systematically summarizes recent advancements in CeO 2 nanozymes: First, it elaborates on cutting‐edge synthetic methodologies, encompassing self‐supported strategies (calcination, hydrothermal, and sol–gel) and carrier‐mediated approaches (small‐molecule compounds, macromolecular compounds, and nanomaterials), with comparative analysis of their respective merits and limitations. Second, the catalytic mechanism is comprehensively elucidated, particularly focusing on the modulation of electron transfer kinetics and surface adsorption energies in metal/nonmetal hybrid systems. By optimizing oxygen vacancy concentration to regulate Ce 3+ /Ce 4+ redox cycling dynamics, significant enhancement in redox efficiency and catalytic stability can be achieved, enabling precise enzyme‐like activity regulation. Furthermore, the review comprehensively summarizes breakthrough applications in multidimensional biomedical fields, including precision tumor therapy, intelligent antibacterial systems, inflammatory microenvironment regulation, and ultrasensitive biosensing. This work establishes a theoretical framework for structure‐activity relationship‐guided rational design of high‐performance CeO 2 nanozymes and delineates their potential translational applications in precision medicine.
Peer Support for Caregivers: An Acute Care Quality Improvement Initiative
Smiley, Adrianne, Vitagliano, Luis, Wold, Angela K., Mailloux, Tish, Hansen, Beverly, Strader, Kelli D., Khera, Nandita , Burns, Michelle R., Vitagliano, Lynne M, Hansen, Beverly B, Smiley, Adrianne , Griffin, Joan M. , Strader, Kelli D. , Chesak, Sherry S.

American Journal of Medical Quality | July 1, 2025 | Volume: 40 | Issue: 4 | Pages: 208-209

10.1097/jmq.0000000000000249 | PMID 40588835 Get It

I-131 Uptake in a Benign Diaphragmatic Mesothelial Cyst Mimicking Thyroid Cancer Metastasis on Post-therapy SPECT/CT
Bilgin, Cem , Bilgin, Gokce Belge , Dundar, Bilge , Kapplinger, Jamie D., Bogsrud, Trond Velde , Durski, Jolanta M. , Hallanger Johnson, Julie E, Hallanger‐Johnson, Julie

Clinical Nuclear Medicine | July 1, 2025 | Volume: 50 | Issue: 10 | Pages: 958-959

10.1097/rlu.0000000000005923 | PMID 40590084 Get It

Radioiodine ablation therapy is commonly used for patients with well-differentiated thyroid cancer. False-positive radioiodine uptake in benign cystic lesions on post-therapy SPECT/CT presents a recognized diagnostic challenge. Here, we present the case of a 33-year-old woman who underwent total thyroidectomy, followed by I-131 radioiodine therapy. Her post–I-131 therapy SPECT/CT revealed incidental radioiodine uptake in a diaphragmatic mesothelial cyst, prompting further investigation. She subsequently underwent a dedicated liver MRI and excision biopsy, both of which were negative for thyroid cancer metastasis. This case highlights the importance of identifying benign sources of radioiodine uptake to avoid unnecessary interventions.
Alzheimer’s Disease Lipidome: Elevated Cortical Levels of Glycerolipids in Subjects with Mild Cognitive Impairment (MCI) but Not in Non-Demented Alzheimer’s Neuropathology (NDAN) Subjects
Wood, Paul L. , Cebak, John E., Beger, Aaron W.

Journal of Dementia and Alzheimer's Disease | July 1, 2025 | Volume: 2 | Issue: 3 | Pages: 20

10.3390/jdad2030020 Get It

Background/Objectives: Abnormal brain glycerolipid metabolism has been reported for Alzheimer’s disease (AD). This includes both diacylglycerols (DGs) and monogalactosyl-DGs (MGDGs), which are elevated in AD subjects. While DGs are also elevated in subjects with mild cognitive impairment (MCI), MGDGs have not yet been examined at this early stage of cognitive impairment. Methods: MGDG, triacylglycerol (TG), and ether glycerolipid levels in the cerebral cortex gray matter of controls, MCI, and non-demented Alzheimer’s neuropathology (NDAN) subjects were monitored by high-resolution mass spectrometry (<2 ppm mass error). Results: MGDG, MGDG ether, DG ether, and TG levels were elevated in the cerebral cortex of MCI but not NDAN subjects. Conclusions: A diverse array of glycerolipids was elevated in MCI subjects, suggesting a role in cognitive dysfunction. This suggestion is further supported by the maintenance of normal glycerolipid levels in NDAN subjects with amyloid accumulation but not cognitive deficits. Our data clearly indicate that while complex lipid alterations occur in MCI subjects, relative to controls 20 years younger, no such lipid alterations occur in NDAN subjects. While amyloid deposition in MCI is not involved in the observed lipid alterations, other ongoing neuropathologies may contribute to changes in lipid dynamics and vice versa.
Psychosis in early onset Parkinson's disease: A retrospective cohort study in southeast Minnesota
Derhab, Mohamed , Mullan, Aidan F. , Turcano, Pierpaolo , Camerucci, Emanuele, Piat, Capucine , Ghoniem, Khaled , Bower, James H., Savica, Rodolfo , Dehnavi, Ali Zare, Savica, Rodolfo , Mullan, Aidan , Camerucci, Emanuele , Dehnavi, Ali Zare

Journal of Parkinson’s Disease | July 1, 2025 | Volume: 15 | Issue: 6 | Pages: 1078-1085

10.1177/1877718x251354978 | PMID 40589144 Get It

Background Early onset Parkinson's disease (EOPD), defined as Parkinson's disease (PD) diagnosed before age 50, often presents unique challenges compared to late-onset PD, particularly with regard to non-motor symptoms. Psychosis in EOPD is associated with increased functional impairment and may lead to a higher mortality risk. Objective Our study is aimed to determine the prevalence of psychosis in EOPD patients and its impact on all-cause mortality, along with examining the effects of antipsychotic medications and Selective Serotonin Reuptake Inhibitors (SSRIs) on mortality in EOPD patients. Methods Our retrospective cohort included EOPD patients diagnosed between 1990 and 2022 at Mayo Clinic, Rochester, Minnesota. Psychosis was defined using the National Institute of Neurological Disorders and Stroke/the National Institute of Mental Health (NINDS/NIMH) Work Group criteria. Cox proportional hazards models were used to analyze the association of psychosis and medications with mortality. Results Of 829 patients with EOPD, 158 (19.1%) developed psychosis at a median of 12.1 years after PD motor symptom onset. Psychosis was significantly associated with increased mortality in unadjusted (HR = 4.31, 95% CI: 2.59–7.18, p < 0.001) and adjusted (HR = 3.55, 95% CI: 2.10–6.01, p < 0.001) models. No significant difference in mortality risk was observed between patients treated with antipsychotics or SSRIs versus those who were not. Conclusions Psychosis is a possible complication in EOPD and is associated with a significant increase in all-cause mortality. The use of antipsychotics and SSRIs did not significantly alter the mortality risk in these patients. Further research is needed to understand the mechanisms driving this association and to develop tailored interventions.
A supervised machine learning approach for predicting the need for postsurgical intervention in acromegaly
Shinya, Yuki , Hong, Sukwoo , Palit, Sandhya R. , Erickson, Dana , Sáez-Alegre, Miguel , Meyer, Fredric B. , Atkinson, John L. D., Herndon, Justine S, Pinheiro Neto, Carlos, Shinya, Yuki , Ghaith, Abdul Karim , Herndon, Justine , Bancos, Irina , Morshed, Ramin A. , Pinheiro‐Neto, Carlos , Gompel, Jamie J. Van

Neurosurgical Focus | July 1, 2025 | Volume: 59 | Issue: 1 | Pages: E10

10.3171/2025.4.focus2597 | PMID 40591978 Get It

OBJECTIVE Patients with growth hormone (GH)–secreting pituitary adenomas (PAs) experience various symptoms and comorbidities, which can ultimately lead to increased mortality. This study aimed to develop and validate a machine learning (ML) model for predicting long-term outcomes in patients with GH-secreting PAs following endonasal transsphenoidal surgery (ETS). METHODS The authors conducted a retrospective three-institution cohort study that included patients with GH-secreting PAs treated with ETS between 2013 and 2023. Clinical, radiological, and biochemical data were collected. The main outcome of interest was the intervention-free rate (IFR) after primary ETS. Supervised ML algorithms, including decision trees and random forests, were developed to predict the IFR. Model performance was evaluated using area under the receiver operating characteristic curve (AUROC) and Shapley Additive Explanations (SHAP) values. RESULTS The median follow-up for 100 patients with GH-secreting PAs (53% female) was 64 months (range 1–130 months). Additional intervention for persistent or recurrent acromegaly was required in 32% of patients. Following primary ETS alone, the 3-year IFR was 70% and the 5-year IFR was 67%. Multiple ML models were developed and evaluated using AUROCs. The decision tree analysis achieved an accuracy of 81% and emphasized the importance of both gross-total resection (GTR) and patient age in determining the long-term IFR. To better understand the factors that contributed to model performance, SHAP analysis was applied to the best-performing model. The SHAP dependence plots showed that key factors associated with a longer IFR included tumor size < 9 mm, GTR, patient age > 65 years, and Knosp grade 0. CONCLUSIONS This ML model offers a more nuanced and potentially more accurate approach to identify patients more likely to develop recurrent or persistent acromegaly following primary ETS and require additional treatment. Following external validation, this ML model could improve personalized treatment planning and follow-up strategies and enhance patient care and resource allocation in clinical practice.